2023-08-17T08:59:19-07:00 2022-12-31 461592906 Jones Simkins LLC 1011 West 400 North Suite 100 Logan UT 84321 990 2022-01-01 201829529 THE INSTITUTE FOR ETHNOMEDICINE INC DBA BRAIN CHEMISTRY LABS INST 8013756214 PO BOX 3464 JACKSON WY 83001 PAUL ALAN COX PHD Executive Dir. 8013194335 2023-08-17 true PAUL ALAN COX PHD 999009999 true RICK E ARNELL CPA P01337052 4357521510 0 AAL1 IAL1 FAL1 2022 2023-04-26 12:10:37Z X PAUL ALAN COX PHD PO BOX 3464 JACKSON WY 83001 3837563 false X WWW.ETHNOMEDICINE.ORG X 2004 WY THE INSTITUTE FOR ETHNOMEDICINE SEARCHES FOR NEW CURES BY STUDYING PLANT MEDICINE AND PATTERNS OF WELLNESS AND DISEASE AMONG INDIGENOUS PEOPLE. 13 11 5 0 3085775 1747535 119771 89500 27125 0 3175275 1894431 0 0 1147256 1220292 0 102211 2088067 1590718 3235323 2811010 -60048 -916579 4594183 4266357 24356 612114 4569827 3654243 THE INSTITUTE FOR ETHNOMEDICINE SEARCHES FOR NEW CURES BY STUDYING PLANT MEDICINE AND PATTERNS OF WELLNESS AND DISEASE AMONG INDIGENOUS PEOPLE. false false 2343147 119771 RESEARCH BY THE INSTITUTE AND MEMBERS OF OUR GLOBAL SCIENTIFIC CONSORTIUM IDENTIFIED THE AMINO ACID L-SERINE AS A POTENTIAL DRUG CANDIDATE. THE INSTITUTE HAS STUDIED THE POTENTIAL OF L-SERINE AS A NOVEL THERAPY FOR THE TREATMENT OF ALS AND OTHER NEURODEGENERATIVE ILLNESSES THROUGH IN VITRO AND IN VIVO EXPERIMENTS, AS WELL AS FDA-APPROVED HUMAN CLINICAL TRIALS. THESE EXPERIMENTS SUGGEST THAT WHILE L-SERINE AT THE DOSES STUDIED CANNOT STOP OR REVERSE NEURODEGENERATION ASSOCIATED WITH ALS, THAT L-SERINE MAY SLOW DISEASE PROGRESSION. 2343147 true true false false false false false false false false true false false false true false true false false false false false false false false false false false false true false false false false false false true false false false false false false false false false false true 17 0 false 5 true false false false false false false false 0 false false false false false false false X 13 11 true false false false false false false true true false false true true true true true true true false false X CINDY BUTERA 3077338377 PO BOX 3464 JACKSON WY 83001 PAUL ALAN COX PHD Executive Dir. 40.00 0.00 X X 268718 0 60587 SANDRA BANACK SENIOR SCIENTIST 40.00 0.00 193540 0 52857 JAMES METCALF SENIOR SCIENTIST 40.00 0.00 148125 0 40403 MARILYN ASAY EXECUTIVE ASSISTAN 40.00 0.00 115830 0 45848 RACHAEL DUNLOP SR RESEARCH FELLOW 40.00 0.00 116558 0 42212 WILLIAM C EGAN III Chairman 4.00 0.00 X X 0 0 0 GORDON DEANE Director 4.00 0.00 X 0 0 0 JOSEPH MERRILL Director 4.00 0.00 X 0 0 0 JAMES GORTER Director 4.00 0.00 X 0 0 0 PATRICK HENRY Treasurer 4.00 0.00 X X 0 0 0 DOUGLAS M KINNEY Director 4.00 0.00 X 0 0 0 JOHN WETHERELL Acting Chair 4.00 0.00 X X 0 0 0 MARION CHRISTOPH Director 4.00 0.00 X 0 0 0 ELIZABETH SUSAN SEVERSON Director 4.00 0.00 X 0 0 0 ROBERT PAULSON Director 4.00 0.00 X 0 0 0 DEREK CRAIGHEAD Director 4.00 0.00 X 0 0 0 BERTE HIRSCHFIELD Director 4.00 0.00 X 0 0 0 842771 241907 5 false true false Pillsbury Winthrop Shaw Pittman LLP PO BOX 742262 LOS ANGELES CA 900742262 LEGAL SERVICES 338974 1 1747535 1747535 Research and Licensing 541700 119771 119771 119771 28551 28551 0 0 0 1941706 1943132 -1426 -1426 -1426 0 0 0 0 1894431 119771 27125 0 0 0 0 329305 251155 78150 60000 60000 585758 419473 166285 57705 40400 17305 133554 94720 38834 53970 38858 15112 0 394572 394572 0 0 0 0 27735 27735 0 65742 46691 19051 0 65542 65542 106118 106118 39914 39914 0 49116 6905 42211 0 0 318017 314837 3180 0 LABORATORY EXPENSES 523962 523962 0 2811010 2343147 365652 102211 441372 2900447 2364804 700800 200439 0 0 0 0 0 19200 0 2094363 1436537 951436 657826 0 22300 0 570016 22300 9600 4594183 4266357 24356 21224 590890 24356 612114 X 4569827 3654243 4569827 3654243 4594183 4266357 -916579 995 X false true X true false X 3030567 3017128 4856888 2974775 1747535 15626893 0 0 3030567 3017128 4856888 2974775 1747535 15626893 3602185 12024708 1978 2154 153 43 28551 32879 0 0 15659772 119771 0.76790 0.99970 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 781039 709331 71708 1313324 727206 586118 657826 Operating Lease Liability 590890 590890 1829884 995 -65542 -64547 1894431 1894431 2745468 2745468 65542 65542 2811010 Part XII, Line 4b: Other revenue amounts included on 990 but not included in F/S Cost of Revenues - Royalties $65542 X false false false false false false false false false JAMES METCALF SENIOR SCIENTIST 148125 14813 25590 188528 MARILYN ASAY EXECUTIVE ASSISTAN 115830 11663 34185 161678 PAUL ALAN COX PHD Executive Dir. 268718 26872 33715 329305 RACHAEL DUNLOP SR RESEARCH FELLOW 116558 11756 30456 158770 SANDRA BANACK SENIOR SCIENTIST 193540 19474 33383 246397 Elizabeth Kinney Family Member 60000 Independent Contractor false Schedule L, Part V Supplemental Information Part IV line 1: Elizabeth Kinney is the spouse to board member Douglas Kinney and works as the Director of National Development in an independent contractor capacity. Form 990, Part VI, Section A, Line 2 TWO BOARD MEMBERS PERIODICALLY DO BUSINESS TOGETHER. Form 990, Part VI, Section B, Line 11b A COPY OF THE FORM 990 IS ISSUED TO ALL BOARD MEMBERS FOR REVIEW BEFORE BEING FILED. Form 990, Part VI, Section B, Line 12c ANY DIRECTOR, DONOR, OR STAFF MEMBER WHO MAY HAVE A CONFLICT OF INTEREST WILL DISCLOSE THIS POTENTIAL CONFLICT TO THE APPROPRIATE SUPERVISOR, BE IT THE EXECUTIVE DIRECTOR OR CHAIRMAN OF THE BOARD. THE EXECUTIVE DIRECTOR WILL DISCLOSE ANY OF HIS OR HER CONFLICTS TO THE CHAIRMAN OF THE BAORD, AND THE CHAIRMAN WILL DISCLOSE ANY CONFLICTS OF INTEREST TO THE BOARD OF DIRECTORS. IN THE CASE OF A CONFICT OF INTEREST OF A DIRECTOR, THAT DIRECTOR WILL RECLUSE HIMSELF OR HERSELF FROM ANY VOTE ON THE PROPOSED ACTION. IN CASES OF RELATED PARTY TRANSACTIONS, THESE TRANSACTIONS WILL BE APPROVED IN ADVANCE IN WRITING BY EITHER THE EXECTUIVE DIRECTOR OR THE CHAIRMAN OF THE BOARD AND FLAGGED FOR THE EXTERNAL AUDITORS TO EXAMEN DURING THE ANNUAL AUDIT. DIRECTORS ARE ASKED ANNUALLY TO DISCLOSE ANY CONFLICTS OF INTEREST TO THE CHAIR, AND THE CHAIR WILL MONITOR AND ENFORCE COMPLIANCE WITH THIS POLICY. Form 990, Part VI, Section B, Line 15a THE COMPENSATION OF THE CEO AND EXECUTIVE DIRECTOR WILL BE DETERMINED BY A COMMITTEE COMPOSED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS SELECTED BY THE CHAIRMAN. TO ASSIST IN DETERMINING COMPENSATION, THE CEO WILL BE ASKED TO PROVIDE COMPARABLE SALARY DATA FOR OTHER PROFESSIONALS OF SIMILAR EDUCATION, TRAININGS, AND RESPONSIBILITY FROM UNIVERSITIES AND OTHER MEDICAL RESEARCH FACILITIES. THE ANNUAL COMPENSATION WILL BE DETERMINED BY THE COMPENSATION COMMITTEE AND CONTEMPORANEOUS SUBSTANTIATION OF THE DELIBERATION AND DECISIONS OF THE COMMITTEE WILL BE RETAINED BY THE CHAIRMAN OF THE BOARD. Form 990, Part VI, Section C, Line 19 ALL GOVERNING DOCUMENTS, POLICIES, AND FINANCIAL STATEMENTS ARE MADE AVAILABLE UPON REQUEST.